Anti-HLA DR + HLA DP antibody [HL-40]
| Name | Anti-HLA DR + HLA DP antibody [HL-40] |
|---|---|
| Supplier | Abcam |
| Catalog | ab8085 |
| Prices | $390.00 |
| Sizes | 100 µg |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG2a |
| Clone | HL-40 |
| Applications | WB FC ICC/IF ICC/IF IP |
| Species Reactivities | Human, Pig |
| Antigen | Burkitt lymphoma cell line Raji |
| Description | Mouse Monoclonal |
| Gene | HLA-DPB1 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
![Human peripheral blood lymphocytes stained with ab8085 (red line). Human whole blood was processed using a modified protocol based on Chow et al, 2005 (PMID: 16080188). In brief, human whole blood was fixed in 4% formaldehyde (methanol-free) for 10 min at 22°C. Red blood cells were then lyzed by the addition of Triton X-100 (final concentration - 0.1%) for 15 min at 37°C. For experimentation, cells were treated with 50% methanol (-20°C) for 15 min at 4°C. Cells were then incubated with the antibody (ab8085, 0.01μg/1x106 cells) for 30 min at 4°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H&L) (ab150113) at 1/2000 dilution for 30 min at 4°C. Isotype control antibody (black line) was mouse IgG2a [ICIGG2A] (ab91361, 1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >30,000 total events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. Gating strategy - periphera](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_3/2604_ab8085-3-ab8085FC.jpg)
Human peripheral blood lymphocytes stained with ab8085 (red line). Human whole blood was processed using a modified protocol based on Chow et al, 2005 (PMID: 16080188). In brief, human whole blood was fixed in 4% formaldehyde (methanol-free) for 10 min at 22°C. Red blood cells were then lyzed by the addition of Triton X-100 (final concentration - 0.1%) for 15 min at 37°C. For experimentation, cells were treated with 50% methanol (-20°C) for 15 min at 4°C. Cells were then incubated with the antibody (ab8085, 0.01μg/1x106 cells) for 30 min at 4°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H&L) (ab150113) at 1/2000 dilution for 30 min at 4°C. Isotype control antibody (black line) was mouse IgG2a [ICIGG2A] (ab91361, 1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >30,000 total events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. Gating strategy - periphera
HeLa cells were transfected with DR. The cells were fixed in paraformaldehyde and either left unpermeabilized (-Tx) or were permeabilized with 0.2% Triton X-100 (+Tx). DR- and DP-transfected cells were immunostained with ab8085. Nuclei were stained with DAPI.
HeLa cells were transfected with different combinations of a, ß, and Ii constructs as indicated. Lysates were first subjected to immunoprecipitation (IP) with ab8085 before Western blotting (WB) with anti-DP and anti-Ii. H and L indicate the heavy and light chains of the antibodies used for the immunoprecipitation.
Product References
HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and - HLA-DP, HLA-DQ, and HLA-DR have different requirements for invariant chain and
van Lith M, McEwen-Smith RM, Benham AM. J Biol Chem. 2010 Dec 24;285(52):40800-8.
Distinct MHC gene expression patterns during progression of melanoma. - Distinct MHC gene expression patterns during progression of melanoma.
Degenhardt Y, Huang J, Greshock J, Horiates G, Nathanson K, Yang X, Herlyn M, Weber B. Genes Chromosomes Cancer. 2010 Feb;49(2):144-54.
CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in - CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in
Ait-Tahar K, Barnardo MC, Pulford K. Cancer Res. 2007 Mar 1;67(5):1898-901.
B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ - B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ
Momburg F, Herrmann B, Moldenhauer G, Moller P. Int J Cancer. 1987 Nov 15;40(5):598-603.
Characterization of seven new monoclonal antibodies against human DR, DR + DP and - Characterization of seven new monoclonal antibodies against human DR, DR + DP and
Horejsi V, Nemec M, Angelisova P, Kristofova H, Gorga JC, Hilgert I. Tissue Antigens. 1986 Nov;28(5):288-97.